Document Detail


A study on inhibition mechanism of breast cancer cells by bis-type triaziquone.
MedLine Citation:
PMID:  20371239     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The objectives of this study were to evaluate the antiproliferation effect of a synthetic quinone-containing compound bis-type triaziquone (BTZQ) on breast cancer cells BC-M1 and MCF-7. At a dose of 0.42 and 0.79 microM, BTZQ showed a 50% inhibition on BC-M1 and MCF-7 cell growth after 24 h treatment, respectively, but reduced to 0.2 and 0.61 microM after 48 h. A low toxic effect was observed for skin fibroblast cell after BTZQ treatment for 48 h at a dose from 0.0625-0.25 microM. BTZQ was more effective in inhibiting growth of breast cancer cells than tamoxifen. Additionally, BTZQ-treated BC-M1 cells under hypoxia condition for 48 h exhibited a higher cytotoxicity than under aerobic condition. Cell cycle analysis revealed the arrest of BC-M1 cells at G2/M phase, with accumulation of apoptotic cells at the sub-G1 phase being enhanced following a rise in dose. The expression levels of caspase-3, caspase-8 and caspase-9 were elevated in both dose- and time-dependent responses. Western blot analysis indicated that BTZQ may up-regulate expression of cyclin B, p21, p53 and cytochrome c, but down-regulate cdk1 expression in a dose-dependent manner, leading to apoptosis of BC-M1 cells. All these results suggested that BTZQ may be a potential anti-breast cancer drug.
Authors:
Yuh-Ling Lin; Yi-Ting Su; Bing-Huei Chen
Related Documents :
1984409 - Correlation of metabolic stability and altered quaternary structure of oncoprotein p53 ...
8247009 - Complementation by wild-type p53 of interleukin-6 effects on m1 cells: induction of cel...
16293709 - The effect of p53-rnai and p53 knockout on human 8-oxoguanine dna glycosylase (hogg1) a...
19458629 - Inhibition of ksp by arry-520 induces cell cycle block and cell death via the mitochond...
19735649 - Oxaliplatin-induced gamma-h2ax activation via both p53-dependent and -independent pathw...
19464429 - A nuclear budding mechanism in transiently arrested cells generates drug-sensitive and ...
10998569 - Ganglioside molecular species containing c18- and c20-sphingosine in mammalian nervous ...
22046189 - A human head and neck squamous cell carcinoma cell line with acquired cis-diamminedichl...
900519 - Enzymatic isolation of osteoblasts from fetal rat calvaria.
Publication Detail:
Type:  Journal Article     Date:  2010-04-02
Journal Detail:
Title:  European journal of pharmacology     Volume:  637     ISSN:  1879-0712     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-05-31     Completed Date:  2010-09-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1-10     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier B.V. All rights reserved.
Affiliation:
School of Medicine, Fu Jen University, Taipei, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Alkylating / pharmacology*
Apoptosis / drug effects
Blotting, Western
Breast Neoplasms / enzymology,  pathology*
Caspase 3 / metabolism
Caspase 8 / metabolism
Caspase 9 / metabolism
Cell Division / drug effects
Cell Line, Tumor
Dose-Response Relationship, Drug
Female
G2 Phase / drug effects
Humans
Time Factors
Triaziquone / pharmacology*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 68-76-8/Triaziquone; EC 3.4.22.-/Caspase 3; EC 3.4.22.-/Caspase 8; EC 3.4.22.-/Caspase 9

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reactive oxygen species and endothelial function in diabetes.
Next Document:  Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.